Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

British Biotech Response to Recent Press Comment.


Business Editors

British Biotech British Biotech was a British based biotech company.

British Biotechnology Limited was founded in 1986 by former G D Searle managers Keith McCullagh and Brian Richards, [1]
 plc (LSE LSE - Language Sensitive Editor :BBG BBG Brooklyn Botanic Garden
BBG Broadcasting Board of Governors
BBG Bloomberg (financial company)
BBG Bundesbeamtengesetz (German Law)
BBG Bergbau-Berufsgenossenschaft (Germany) 
, Nasdaq:BBIOY) has noted the recent press comment regarding Class Law, an English firm of solicitors, and putative claims against the Company in respect of events more than four years ago.

The Company understands that Class Law has been attempting to solicit interest in such claims since at least February 2001 and since such time has also been regularly suggesting that proceedings against the Company are imminent. Such proceedings have not been forthcoming and neither the Company nor its legal advisers, Allen & Overy, have been in receipt of any correspondence pertaining per·tain  
intr.v. per·tained, per·tain·ing, per·tains
1. To have reference; relate: evidence that pertains to the accident.

2.
 to such claims.

The Company has considered the nature of Class Law's putative, but unspecified, claims with its legal advisers and believes them to be without merit or foundation.

This news release contains forward-looking statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
 that reflect the Company's current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:4EUUK
Date:Jun 28, 2002
Words:195
Previous Article:Cytokine PharmaSciences Names Dennis F. Willson President and CEO; Willson also Appointed to Company Board of Directors.
Next Article:Peoples State Bank Announces Transfer From Loan Loss Provision.
Topics:



Related Articles
NEW DATABASE CONTAINS DRUG DISCOVERY/DEVELOPMENT INFO.
Shredding `The Ecologist'.
CROP BUSTERS.
BRITISH BIOTECH SAYS MARIMASTAT OFFERS NO BENEFITS.
AMGEN CONTINUES MONTH'S DOWNWARD SLIP.
RUMORS FLYING OVER AMGEN.
FDA CLEARS THROMBOLYTIC DRUG FOR PHASE II CLINICAL TRIAL.
GPC BIOTECH/DEBIOPHARM SIGN MHC II ANTAGONISTS LICENSE PACT.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles